盐酸埃克替尼片靶向治疗非小细胞肺癌疗效分析

Therapeutic effects of ectinib hydrochloride tablets targeted therapy on NSCLC

目的探讨盐酸埃克替尼片靶向治疗非小细胞肺癌临床疗效。方法选取2017年12月至2020年5月收治的非小细胞肺癌患者86例,根据随机数表法分为靶向组和化疗组,每组43例,靶向组采用盐酸埃克替尼片靶向治疗,化疗组使用培美曲塞联合顺铂化疗治疗,比较2组患者治疗有效率和疾病空置率,观察并比较2组治疗前后卡式功能量表(KPS)评分和肺癌生存质量评价(FACT-1)评分、肿瘤标志物水平[癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原125(A125)]和炎性因子水平[超敏C-反应蛋白(hs-CRP)、白介素-6(IL-6)、白介素-8(IL-8)],并比较2组患者不良反应发生情况。结果靶向组治疗有效率明显高于化疗组(χ^(2)=5.103,P=0.024);靶向组疾病控制率明显高于化疗组(χ^(2)=12.147,P=0.000)。治疗前2组KPS评分和FACT-1评分差异无统计学意义(P>0.05);治疗后靶向组KPS评分和FACT-1评分均高于化疗组,差异有统计学意义(P<0.05)。治疗前2组肿瘤标志物水平差异无统计学意义(P>0.05);治疗后靶向组CEA、CA199和CA125水平均低于化疗组(P<0.05)。治疗前2组炎性因子水平指标差异无统计学意义(P>0.05),治疗后靶向组hs-CRP、IL-6、和IL-8水平明显低于化疗组(P<0.05)。靶向组不良反应发生率明显低于化疗组(χ^(2)=10.033,P=0.002)。结论盐酸埃克替尼片靶向治疗非小细胞肺癌临床疗效优于培美曲塞联合顺铂化疗,可明显改善患者炎性反应,降低肿瘤标志物水平,且不良反应较少,值得临床进一步推广。

Objective To investigate the therapeutic effects of ectinib hydrochloride tablets targeted therapy on non-small cell lung cancer(NSCLC).Methods A total of 86 patients with NSCLC who were treated in our hospital from December 2017 to May 2020 were enrolled in the study,who were divided into observation group and control group according to random digital table,with 43 cases in each group.The patients in observation group were treated by ectinib hydrochloride tablets targeted therapy,however,the patients in control group were treated by pemetrexed combined with cisplatin chemotherapy.The KPS score and FACT-1 score,tumor markers and inflammatory factor levels,and the incidence rate of adverse reactions were observed and compared between the two groups.Results The effective rate and disease control rate in observation group were significantly higher than those in control group(P<0.05).Before treatment there were no significant differences in KPS scores and FACT-1 scores between the two groups(P>0.05).After treatment the KPS scores and FACT-1 scores in observation group were significantly higher than those in control group(P<0.05).Before treatment there were no significant differences in tumor marker levels between the two groups(P>0.05).After treatment the levels of CEA,CA199 and CA125 in observation group were significantly higher than those in control group(P<0.05).Before treatment there were no significant differences in inflammatory factor levels between the two groups(P>0.05).After treatment the levels of hs-CRP,IL-6 and IL-8 in observation group were significantly lower than those in control group(P<0.05).In addition the incidence rate of adverse reactions in observation group was significantly lower than that in control group(P<0.01).Conclusion Therapeutic effects of ectinib hydrochloride tablets targeted therapy on NSCLC are superior to those by pemetrexed combined with cisplatin chemotherapy,the former can significantly improve the inflammatory response of patients,reduce the tumor markers levels,with fewer adverse reactions,therefore,it is worthy of clinical promotion.